India Aiming for a Bigger Piece of the Global Pharma Market

India Aiming for a Bigger Piece of the Global Pharma Market
India is aiming to grab a bigger piece of the global pharmaceutical market and challenge China as the world’s pharmacy. India’s pharma market is the third largest in volume across the globe, and the 14th largest in value.
However, it is poised for more. Analysts expect that the country’s global market share in pharma will swell as the industry is currently valued at $50 billion and is expected to pass $130 billion by 2030.
A slew of governments in the West are in the process of pivoting away from China supply chains, which they view as posing increased risk to business continuity. India is set to benefit from new opportunities from large biotech companies looking to partner with Indian manufacturers for drug development.
India's pharmaceutical industry has seen an 8% year-to-date increase in exports and a 29% boost in this past month alone. The country is benefiting from new growth opportunities caused by greater demand from the U.S. and medicine shortages in Europe. 
What does this mean for me?
India is already one of the biggest suppliers of low-cost vaccines in the world, making up 60% of global vaccine production. The country leads the world in generic medicine production, accounting for some 20% of global demand.
Now, the country wants to gate crash the medical devices sector too. With a proven commitment to innovation, quality, and cost-effectiveness, analysts believe it will continue to scoop up market share in this sector as well.
Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.